Docetaxel

Title	Average Rating
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ......	95.00%
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer	80.00%
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen	80.00%
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.	80.00%
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline	70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.	70.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.	70.00%
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep..	70.00%
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.	60.00%
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer.	50.00%
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic	40.00%

Languages